{"id":"W2473614468","doi":"10.1182/blood.v126.23.1982.1982","title":"Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTMÂ chain (HLC) Normalization","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; University of British Columbia; McGill University; Saint John Regional Hospital; Saskatchewan Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Lenalidomide; Busulfan; Multiple myeloma; Maintenance therapy; Internal medicine; Urology; Thalidomide; Surgery; Oncology; Transplantation; Hematopoietic stem cell transplantation; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00118158,0.0007347962,0.00106963,0.0002322632,0.001085644,0.0008297596,0.0009977354,0.0006066579,0.00251073],"category_scores_gemma":[0.0005614205,0.0003318856,0.0006790248,0.0006391457,0.000769833,0.000276195,0.0003871178,0.001643036,0.0003020442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01313525,"about_ca_system_score_gemma":0.0245569,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5145344,"about_ca_topic_score_gemma":0.8655012,"domain_scores_codex":[0.9995376,0.0001420289,0.00001430714,0.00006903273,0.00009581851,0.0001412732],"domain_scores_gemma":[0.9994734,0.00002456365,0.00005765171,0.00001991085,0.00005523069,0.0003692372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.636864,0.02875219,0.04855214,0.001102374,0.003345185,0.0003652014,0.0006548999,0.005305789,0.04422701,0.001632111,0.0288218,0.2003773],"study_design_scores_gemma":[0.4374693,0.2352352,0.2682215,0.0002067679,0.003212919,0.0006221265,0.0004070324,0.004125631,0.009916405,0.000596733,0.03986093,0.0001253614],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828252,0.002640058,0.0002719043,0.001812848,0.0001251199,0.00279707,0.003474345,0.00008386257,0.005969549],"genre_scores_gemma":[0.9851017,0.001551154,0.002116123,0.001532261,0.00009508131,0.0008296288,0.003541742,0.00002302856,0.005209192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4854656,"threshold_uncertainty_score":0.9766493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06906379413577311,"score_gpt":0.3158552214971248,"score_spread":0.2467914273613517,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}